Odds of Opioid Misuse Lower in States With Medical Cannabis Laws
By Elana Gotkine HealthDay Reporter
THURSDAY, Jan. 16, 2025 -- For individuals reporting cannabis use, the odds of opioid misuse are reduced among individuals in states with medical cannabis legalization (MCL), according to a study published in the February issue of the International Journal of Drug Policy.
Silvia S. Martins, M.D., Ph.D., from the Columbia University Mailman School of Public Health in New York City, and colleagues used data from the National Survey on Drug Use and Health from 2015 to 2019 to estimate cannabis law associations with opioid misuse and use disorder.
The researchers observed no associations for MCL or recreational cannabis legalization (RCL) with changes in the odds of any opioid outcome overall. Decreased odds of past-year opioid misuse were seen among individuals in states with MCL versus those without cannabis laws, after restricting the analyses to respondents reporting past-year cannabis use (adjusted odds ratio, 0.57). There was no association seen for RCLs with changes in the odds of any opioid outcome beyond MCL adoption.
"One important issue to consider is that compared to MCLs, relatively fewer states have adopted RCLs+MCLs, and most laws have been adopted within the past decade," Martins said in a statement. "Therefore, the impact of RCLs+MCLs may become clearer as more states adopt these laws and as post-law observation time accumulates."
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted January 2025
Read this next
BRCA Mutations Linked to Breast Implant Anaplastic Large Cell Lymphoma
WEDNESDAY, June 25, 2025 -- For women with breast cancer (BC), BRCA mutations are associated with increased risk of developing breast implant–associated anaplastic large...
ADA: Orforglipron Reduces Glycated Hemoglobin in Early Type 2 Diabetes
WEDNESDAY, June 25, 2025 -- The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 weeks in adults with early...
Paternal Mental Distress Linked to Poorer Offspring Development
WEDNESDAY, June 25, 2025 -- Paternal mental distress is associated with poorer child development, according to a study published online June 16 in JAMA Pediatrics. Genevieve Le...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.